Kamada Ltd.
Kibbutz Beit Kama M.P.
Negev
85325
Tel: 07-991-2082
Fax: 07-991-2083
238 articles with Kamada Ltd.
-
Kamada Reports Strong Fiscal Year and Fourth Quarter 2022 Financial Results, and Provides 2023 Guidance Representing Significant Profitability Growth
3/15/2023
Kamada Ltd. today announced financial results for the 12 and three months ended December 31, 2022.
-
Kamada Issues 2023 CEO Letter to Shareholders
3/15/2023
Kamada Ltd. today issued a Letter to Shareholders from Amir London, Chief Executive Officer.
-
Kamada to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 15, 2023
3/9/2023
Kamada Ltd. today announced that it will release financial results for the fourth quarter and full year ended December 31, 2022, prior to the open of the U.S. financial markets on Wednesday, March 15, 2023.
-
Kamada Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® at the Company’s Facility in Israel
1/4/2023
Kamada Ltd. today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) to manufacture CYTOGAM® (Cytomegalovirus Immune Globulin Intravenous [Human]) (CMV-IGIV) at its facility in Beit Kama, Israel.
-
Kamada Announces Planned Transition of Chief Financial Officer
12/19/2022
Kamada Ltd. today announced that its Chief Financial Officer (CFO), Chaime Orlev, will transition out of his role to pursue other opportunities, effective March 15, 2023.
-
Kamada Reports Strong Third Quarter Financial Results Demonstrating Successful Strategic Transition and Reiterates 2022 Financial Guidance
11/22/2022
Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced financial results for the three and nine months ended September 30, 2022.
-
Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2022 Financial Results and Host Conference Call on November 22, 2022
11/16/2022
Kamada Ltd. today announced that it will release financial results for the third quarter and first nine months ended September 30, 2022, prior to the open of the U.S. financial markets on Tuesday, November 22, 2022.
-
Kamada Provides Update on Recent Progress Achieved in Ongoing Pivotal Phase 3 Clinical Trial of Inhaled AAT
11/7/2022
Kamada today provided an update on recent progress achieved in its ongoing pivotal Phase 3 InnovAATe clinical trial evaluating the safety and efficacy of the Company’s proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
-
Kamada to Present at the Credit Suisse 31st Annual Healthcare Conference
10/26/2022
Kamada Ltd. announced that Amir London, Chief Executive Officer, will present a corporate overview at the Credit Suisse 31st Annual Healthcare Conference, which will take place November 8 - 10, 2022.
-
Kamada Awarded $22 Million Extension of Canadian Supply Tender
10/19/2022
Kamada Ltd. announced that the Company was awarded an extension of an existing tender from the Canadian Blood Services for the supply of four IgG products, CYTOGAM®, HEPAGAM®, VARIZIG® and WINRHO® SDF, for an additional three years for an approximate total value of $22 million.
-
Kamada to Announce Second Quarter and First Half Ended June 30, 2022 Financial Results and Host Conference Call on August 17, 2022
8/10/2022
Kamada Ltd. today announced that it will release financial results for the second quarter and first half ended June 30, 2022, prior to the open of the U.S. financial markets on Wednesday, August 17, 2022.
-
Mogrify and Astellas have forged a collaboration surrounding in vivo regenerative medicine approaches, while CardiNor inked a distribution deal with IBL-America.
-
Kamada Announces $11.4 Million International VARIZIG® Procurement Agreement
7/6/2022
Kamada Ltd. announced that it has secured an $11.4 million agreement to supply VARIZIG® to an undisclosed international organization, operating principally in Latin America.
-
Kamada Strengthens Senior Leadership Team; Furthering Commitment as a Fully Integrated Global Leader in the Specialty Plasma-Derived Therapeutics Market
6/15/2022
Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announced today the promotions of Shavit Beladev to Vice President responsible for the Company's Plasma Operations, and Boris Gorelik to Vice President of Business Development and Strategic Programs, both reporting to Kamada's CEO, Amir London.
-
Kamada to Host a Virtual Analysts and Investors Meeting to Review its Growth Catalysts
6/1/2022
Kamada Ltd. announced that it will host a virtual analysts and investors meeting on Tuesday, June 7, 2022, at 12:00 PM Eastern Time to review its growth catalysts.
-
Kamada Reports First Quarter 2022 Financial Results; Reiterates Revenue and Profitability Guidance with Significant Growth Expected in 2022
5/17/2022
Kamada Ltd. announced financial results for the three months ended March 31, 2022.
-
Kamada Announces Expansion of Pivotal Phase 3 Clinical Trial of Inhaled AAT to Additional Six Clinical Sites Across Europe; and Positive Recommendation by DSMB to Continue the Trial Without Modification
5/17/2022
Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today provided an update on recent progress achieved in its ongoing pivotal Phase 3 InnovAATe clinical trial evaluating the safety and efficacy of the Company’s proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
-
Kamada to Announce First Quarter Ended March 31, 2022 Financial Results and Host Conference Call on May 17, 2022
5/11/2022
Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that it will release financial results for the first quarter ended March 31, 2022, prior to the open of the U.S. financial markets on Tuesday, May 17, 2022.
-
Biopharma and life sciences companies continue to strengthen their executive teams and boards with this week’s Movers & Shakers.
-
Kamada Reports Fiscal Year and Fourth Quarter 2021 Financial Results; Provides Revenue and Profitability Guidance with Significant Growth Expected in 2022
3/15/2022
Kamada Ltd., a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announced financial results for the 12 and three months ended December 31, 2021.